Revocation of Pharmaceutical Licenses and Permits / Suspension of Operations
First written in FY2018. 3 of 4 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2021: 2 of 14 companies on the "Worse" side.
16 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The Group strictly complies with all applicable conditions and laws and regulations in order to obtain and maintain these licenses and other approvals, and no administrative action involving their revocation or suspension has occurred as of the present time.」
While describing the risks of license revocation and suspension of operations, the company reconfirms that no administrative action has occurred as of the present time. - FY2021RestatedAnnual report
「As of the present time, no administrative action involving the revocation or suspension of these licenses or other approvals has occurred. However, if the relevant authorities impose adverse administrative measures, such as revoking these licenses or suspending operations, as a result of inadvertent violations of laws and regulations or other factors,」
The company reconfirms the risks of license revocation or suspension under the Pharmaceuticals and Medical Devices Act, GMP, GQP and related laws and regulations, as well as the fact that no administrative action has occurred as of the present time. - FY2019RestatedAnnual report
「However, if the relevant authorities impose adverse administrative measures, such as revoking these licenses or suspending operations, as a result of inadvertent violations of laws and regulations or other factors, the Group's operating results and financial position may be affected.」
The company reconfirms the risk of license revocation or suspension under the Pharmaceuticals and Medical Devices Act, GMP, GQP and related laws and regulations. - FY2018First statedAnnual report
「If the relevant authorities impose adverse administrative measures, such as revoking these licenses or suspending operations, as a result of inadvertent violations of laws and regulations or other factors, the Group's operating results and financial position may be affected.」
Regulatory risk based on compliance with the Pharmaceuticals and Medical Devices Act, GMP, GQP and related laws and regulations. The company states that no administrative action involving license revocation or suspension has occurred as of the present time.